Benign ulcer of the stomach and duodenum, including those associated with the use of non-steroidal anti-inflammatory drugs; gastroesophageal reflux disease; Zollinger-Ellison syndrome, for the eradication of Helicobacter pylori (in combination with antibiotics).
Lansoprol 30 mg Composition
active substance: lansoprazole
1 capsule contains lansoprazole 15 or 30 mg
auxiliary substances: spherical sugar, lures (E 421), sodium starch (type A), magnesium carbonate, povidone, sucrose, poloxamer, hypromellose, methacrylate copolymer dispersion, talc, triethyl citrate, simethicone.
Gelatin capsule No. 1 contains titanium dioxide (E 171), iron oxide red (E172), iron oxide yellow (E172), patented blue V (E 131), gelatin.
Gelatin capsule No. 2 contains titanium dioxide (E 171), iron oxide red (E172), iron oxide yellow (E172), gelatin.
Lansoprol 30 mg Dosage form
Basic physical and chemical properties:
hard gelatin capsules No. 2 with an orange lid and body, containing spherical micropellets of white or almost white color (15 mg)
hard gelatin capsules No. 1 with a green lid and an orange body, containing spherical micropellets of white or almost white color (30 mg).
Means for the treatment of peptic ulcer and gastroesophageal reflux disease. Proton pump inhibitors. ATX code A02B C03.
Lansoprol 30 mg Pharmacological properties
Lansoprazole inhibits the activity of the H + / K + -ATPase of the proton pump in the parietal cells of the gastric mucosa. Thus, Lansoprol inhibits the final stage of the formation of gastric acid, reduces the amount and acidity of gastric juice, thereby reducing the harmful effect of gastric juice on the mucous membrane.
The degree of suppression is determined by the dose and duration of treatment. Even a single dose of 30 mg of lansoprazole suppresses gastric acid secretion by 70-90%. The onset of action is observed within 1-2 hours and lasts for 24 hours.
Lansoprazole is absorbed in the intestine. In healthy volunteers, when taking 30 mg of lansoprazole, the maximum plasma concentration is 0.75-1.15 mg / l and is reached within 1.5-2 hours. The maximum plasma concentration and bioavailability depend on the specific characteristics of the patient and do not change depending on the frequency of taking the drug.
The binding of the drug to blood plasma proteins is 98%.
Lansoprozole is excreted from the body with bile and urine (only in the form of metabolites – lansoprazole sulfone and hydroxylanesoprazole), while 21% of the drug dose is excreted in the urine per day. The half-life is 1.5 hours.
The half-life is lengthened in patients with severe hepatic impairment and in patients aged 69 and over. In patients with impaired renal function, the absorption of lansoprazole is practically unchanged.
Benign gastric and duodenal ulcers, including those associated with the use of non-steroidal anti-inflammatory drugs, gastroesophageal reflux disease, Zollinger-Ellison syndrome, for the eradication of Helicobacter pylori (in combination with antibiotics).
Lansoprol 30 mg Contraindications
Hypersensitivity to lansoprazole or to any other component of the drug, simultaneous use with atazanavir malignant neoplasms of the digestive tract.